arrow
S

Saranya Sridhar

Sanofi
H指数:27
被引数:4,461

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age

一项关于两种四价季节性流感疫苗(Fluzone®或Flublok®)在18-45岁健康成年人中,单独使用或与两种佐剂(AF03或Advax-CpG55.2)联合使用时的安全性、反应原性和免疫原性的I期研究

VACCINE
IF3.5
2025-04-010
PRE
Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants
2025-01-180
OAAI
GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

GUSELKUMAB诱导恢复中度至重度活动性溃疡性结肠炎的肠道免疫稳态并促进上皮修复

2024-06-010
PRE
Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants

Β-变体重组加强疫苗引起包括Omicron变体在内的SARS-CoV-2的广泛交叉反应中和

HELIYON
IF3.6
2024-03-011
OAAI
Efficacy of a bivalent (D614+B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
2023-11-019
OAAI
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
2023-10-013
OAAI
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

带有AS03佐剂的变体适应SARS-CoV-2重组蛋白疫苗作为授权疫苗的成人助推器的安全性和免疫原性: 一项3期平行组研究

2023-08-018
OAAI
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2 randomised, dose-finding, multicentre study
2022-05-0143
OAAI